Instituto Rosenbusch S.A. Overview
Instituto Rosenbusch is a century-old Argentine animal-health laboratory. It develops, manufactures and sells veterinary biologicals (vaccines for cattle, sheep, goats, horses, dogs and cats) and pharmaceuticals (antiparasitics, endectocides, antibiotics, antimastitics, vitamins and minerals). Products are sold mainly to the Argentine livestock sector through a veterinarian-led commercial model, with exports to more than 50 markets. It is the only veterinary biologicals manufacturer listed on the Buenos Aires exchange. The company is in deep financial distress. It went through a concurso preventivo (court-supervised reorganisation) opened in November 2019. It reported a negative gross margin and negative equity at end-2025. In February 2026 control passed from the founding Balestrini family and associated holding companies to Agro 2000 S.A., a Córdoba-origin agribusiness supplier. The new controller is executing a balance-sheet repair (ARS 1.94 bn debt forgiveness plus an ARS 12.3 bn asset revaluation). The investment case now rests on operational turnaround under new ownership rather than on historical franchise strength.
What the company does
Rosenbusch is a vertically integrated veterinary products manufacturer. It owns its product registrations, runs in-house production of both bacterial/viral biologicals and pharmaceutical formulations at its Buenos Aires facility, and sells through its own commercial organisation. Data-vendor descriptions derived from the company's filings divide the portfolio into Biological Products (vaccines for the reproductive-respiratory complex, IBR, BVD, brucellosis, anthrax/carbunclo, clostridial diseases, pneumonia, calf diarrhoea and infectious bovine keratoconjunctivitis; vaccines for sheep, goats, horses and dogs) and Pharmaceutical Products (external and internal antiparasitics, endectocides, antimycotics/bacteriostatics, injectable antibiotics, antimastitics, other chemotherapeutics, vitamins and minerals), plus an Others line ([SA], [TV]).
In addition, the company:
-
markets biolarvicides for environmental control of disease-carrying mosquitoes (dengue, malaria vectors) as an alternative to chemical fumigation ([BdC], [BW]);
-
has developed probiotics aimed at improving bovine gut health and lowering methane emissions ([BdC]);
-
offers specialised diagnostic services ([BdC]);
-
historically was also involved in slaughtering and meat products, according to an older data-vendor profile. Whether that activity continues is not publicly disclosed ([INV]).
Business and revenue model
| Dimension | Characterisation | Evidence |
|---|---|---|
| Revenue model | Almost entirely product sales (manufactured goods). Service revenue (diagnostics) is not separately disclosed and is believed to be immaterial. No subscription or licensing revenue disclosed. | [SA], [BdC] |
| Product mix FY2025 | Pharmaceuticals 55.9%, Biologicals 41.1%, Others ~3.0% of sales | Company FY2025 annual report as summarised in [RAVA] |
| Product mix 9M 2024 (local market) | Pharmaceuticals 43.13%, Biologicals 54.76% | [BdC] |
| Market mix FY2025 | Domestic 68.8%, exports ~31.2% | [RAVA] |
| Channel | Commercial model built on veterinarians based throughout Argentina. The founder believed only veterinarians should sell veterinary products. | [BdC], [RAVA] profile |
| Value-chain position | Upstream manufacturer (R&D, registration, production). Sells to distributors, veterinary practices and producers. Competes with multinational and domestic originators and generic formulators. | Analyst assessment |
| Customer types | Cattle ranchers and feedlots (beef and dairy), sheep/goat producers, equine owners, companion-animal veterinary clinics, public-health and municipal vector-control programmes (biolarvicides), export distributors | [BdC], [IC], [BW] |
| End-markets | Argentine livestock health (core); companion animals; vector control; export markets (Latin America, Middle East incl. Libya, Oman, Dubai) | [BdC] |
Company self-description
The company describes itself, through its long-standing exchange profile, as dedicated exclusively to animal health, run by the third generation of the founding family, with a commercial model built on veterinarians across the country. It also claims a place among Argentina's 300 most important companies and leadership in many market segments, and stresses that it is the only company in its sector listed on the Buenos Aires exchange ([RAVA] profile text). That profile predates the February 2026 change of control. The "third generation of the family" statement is no longer accurate.
Independent characterisation
Analytically, Rosenbusch is a sub-scale, distressed domestic animal-health manufacturer with a heritage brand. Its strengths lie in clostridial, reproductive and anthrax (carbunclo) biologicals, where local registrations, cold-chain distribution and veterinarian relationships matter. In FY2025 it was squeezed between:
-
multinationals (Zoetis, MSD Animal Health, Boehringer Ingelheim, Elanco, Ceva) with far larger R&D budgets; and
-
well-capitalised national laboratories (Biogénesis Bagó, CDV, Over, König, Holliday-Scott).
Revenue at FY2025 levels (≈ ARS 6.4 bn, roughly USD 4–5 M) makes it a micro-cap. Its economics are dominated by working-capital financing costs, FX exposure on imported inputs, and the Argentine inflation/devaluation cycle. The FY2025 collapse in biological sales (−61.4% in pesos) suggests that funding constraints impaired production and supply, rather than a pure demand shock. Management's own commentary cited lack of access to working-capital credit.
Strategy
Stated strategy
No formal strategy document, investor day, or medium-term plan from the new controller is publicly available. The FY2025 annual report, as summarised in [RAVA], states that Agro 2000 has designed an investment plan aimed at repairing the company's delicate financial position and giving it more certainty about the future. Strategic themes identifiable from filings and press:
-
Balance-sheet restoration. Reverse negative equity to avoid dissolution risk under corporate law and to restore credit access.
-
Conversion of shareholder credits into equity. The incoming shareholders committed to turning acquired credits into irrevocable capital contributions; the 2026 assembly agenda includes capitalisation of credits from Agro 2000 and the IRSA-named guarantee trust.
-
Vertical integration into the controller's agribusiness distribution. [IP] notes the acquisition lets Agro 2000 extend into veterinary manufacturing with a brand, registrations, industrial capacity and over a century of history.
-
Export diversification (Middle East, Latin America), pursued since 2024 ([BdC]).
-
Innovation niches: biolarvicides for dengue control and methane-reducing bovine probiotics ([BdC]).
Initiatives register (last 24 months)
| Date | Initiative | Type | Quantification | Source |
|---|---|---|---|---|
| 2024–Jan 2025 | Export push into Libya, Oman, Dubai via local distributors | Market expansion | Exports USD 1.3 M in 9M 2024 | [BdC] |
| Pre-2025 (undated) | Biolarvicide for mosquito control (dengue) | New business / ESG | — | [BdC] |
| Pre-2025 (undated) | Methane-reducing bovine probiotics | R&D / ESG | — | [BdC] |
| Feb 2026 | Agro 2000 investment plan to repair finances | Turnaround programme | Not quantified publicly | [RAVA] |
| Feb 2026 | Commitment to convert former shareholders' credits into irrevocable capital contributions | Recapitalisation | Not quantified | [RAVA] |
| 11 Sep 2026 | Agro 2000 irrevocable offer to forgive all intercompany debt | Recapitalisation | ARS 1,941,213,008 | [RAVA], [IP] |
| 11 Sep 2026 | Technical revaluation of real estate, machinery and installations; adoption of the IAS 16 revaluation model | Accounting / equity repair | +ARS 12,328,258,993 gross; deferred tax ARS 3,082,064,648; net ≈ ARS 9,246 M | [RAVA], [IP] |
| Pending 2026 | Shareholders' assembly to approve the debt forgiveness and credit capitalisations | Corporate action | Combined equity improvement ≈ ARS 11,187 M | [IP] |
Guidance
Management has published no financial guidance or medium-term targets. There are no disclosed cost-reduction programmes or ESG targets.
Products & Services
A complete SKU-level catalogue is not publicly available (the company website is offline). The table lists every product or category identifiable from public sources. Launch years and pricing are not publicly disclosed unless stated.
Biological Products
| Product / line | Description and indication | Target customer | Source |
|---|---|---|---|
| Reproductive-respiratory complex vaccines (IBR, BVD and related) | Polyvalent vaccines against infectious bovine rhinotracheitis, bovine viral diarrhoea and associated reproductive/respiratory pathogens | Beef and dairy herds | [SA] |
| Reprocultivac | Named reproductive-disease vaccine for cattle | Cow-calf operations | [CRAFT] |
| Brucellosis vaccine | Vaccine against bovine brucellosis, a regulated disease in Argentina | Cattle producers (official programmes) | [SA], [BdC] |
| Carbunclo (anthrax) vaccine | Anthrax vaccine; vaccination compulsory in Buenos Aires and Santa Fe provinces. The company invested in production automation to scale it. | Cattle producers in endemic provinces | [IC], [BdC] |
| Clostridial vaccines | Polyvalent vaccines against clostridial diseases (gas gangrene, enterotoxaemia, bacillary haemoglobinuria, etc.) | Cattle, sheep, goats | [SA], [CRAFT] |
| Bacillary haemoglobinuria vaccine | Clostridial vaccine | Cattle | [CRAFT] |
| Botulism vaccine (types C and D) | Toxoid vaccine against botulism | Cattle | [CRAFT] |
| Tetanus vaccine | Tetanus toxoid | Equines, other livestock | [CRAFT] |
| Pneumonia vaccines | Respiratory disease prevention | Calves, feedlot cattle | [SA] |
| Calf-diarrhoea (neonatal) vaccines | Dam vaccination to protect calves against neonatal diarrhoea | Cow-calf operations | [SA] |
| Infectious bovine keratoconjunctivitis vaccine | Vaccine against "pink eye" | Cattle | [SA], [CRAFT] |
| Equine vaccines | Vaccines for horses | Equine owners, studs | [SA] |
| Sheep and goat vaccines | Small-ruminant vaccines | Sheep and goat producers | [SA] |
| Canine vaccines | Companion-animal vaccines | Veterinary clinics | [SA], [BdC] |
| Cultivac Felina | Feline vaccine | Veterinary clinics | [CRAFT] |
Pharmaceutical Products
| Product line | Description | Target customer | Source |
|---|---|---|---|
| External antiparasitics | Ectoparasiticides (ticks, lice, flies, mange) | Livestock and companion animals | [SA], [BdC] |
| Internal antiparasitics | Anthelmintics | Livestock and companion animals | [SA], [BdC] |
| Endectocides | Combined internal and external parasite control (macrocyclic-lactone class, per category name) | Cattle | [SA] |
| Antimycotics / bacteriostatics | Antifungal and bacteriostatic preparations | Livestock and companion animals | [SA] |
| Injectable antibiotics | Parenteral antimicrobials | Livestock | [SA] |
| Antimastitics | Intramammary products for bovine mastitis | Dairy farms | [SA] |
| Other chemotherapeutics | Miscellaneous therapeutics | Livestock | [SA] |
| Vitamins and minerals | Nutritional supplements (injectable/oral) | Livestock | [SA] |
| Hormonal treatments | Reproductive hormones (listed in older profile) | Cattle breeding | [INV] |
Other offerings
| Offering | Description | Target customer | Source |
|---|---|---|---|
| Biolarvicides | Biological larvicides for environmental control of mosquitoes that transmit dengue and malaria; a sustainable alternative to fumigation | Municipal and public-health vector-control programmes | [BdC], [BW] |
| Bovine probiotics | Probiotics that promote intestinal health in cattle and reduce methane emissions | Cattle producers | [BdC] |
| Diagnostic services | Specialised veterinary diagnostics | Veterinarians, producers | [BdC] |
Financial Narrative
All figures are ARS millions (nominal, as captured by [SA] from company filings) unless stated. FY = year to 31 December. See caveat 1: nominal growth is heavily distorted by inflation.
Income statement
Source: [SA], FY2021–FY2025. Company-reported net results differ (FY2023 ARS 789.6 M per [BdC]; FY2024 ARS −1,745 M and FY2025 ARS −4,539 M per company report via [RAVA]).
Per-share data
Source: [SA]. The company has never paid dividends ([TV]). Weighted shares ≈ 42.59 M in all years (no issuance or buybacks).
Margins and growth
Source: [SA]; SG&A ratio computed by analyst. Nominal revenue CAGR FY2021–FY2025 = 43.2% (ARS 1,523 M to 6,404 M). Argentine CPI rose about 95% in 2022, 211% in 2023 and 118% in 2024, so real revenue contracted materially over the period. Company-reported gross margin was 46.3% in FY2024, per the FY2025 annual report ([RAVA]).
Interim and trailing data (FY2026 to date)
Sources: Q1 2026 from [IP] (CNV filing); TTM from [SA]. The positive TTM net income comes entirely from a ARS 2.9 bn tax benefit and a ARS 1.6 bn FX gain. The business still lost money at the operating level (TTM EBIT ARS −3.3 bn).
Balance sheet
Source: [SA]. Discrepancy: [IP] cites the company's 31 Dec 2025 equity as ARS −1,946.5 M (restated to Mar-2026 currency) versus [SA] ARS −526.2 M total equity.
Post-balance-sheet developments (2026):
Sources: Mar-2026 and pro-forma from [IP]; Jun-2026 from [SA]. The Jun-2026 balance sheet appears to already reflect the ARS 12.33 bn technical revaluation (PP&E jumps from ARS 1.65 bn to 14.44 bn) and the related deferred-tax liability within other long-term liabilities (ARS 7.5 bn). The Jun-2026 retained-earnings figure suggests reclassification or absorption of losses against reserves. Detail is not publicly disclosed.
Cash flow
Source: [SA]. TTM to Jun-2026: OCF ARS 973 M, capex ARS 8.9 M, FCF ARS 964 M, net debt repaid ARS 1,364 M.
Ratios
Sources: ROE, ROA, ROIC, current/quick ratios, D/E, net debt/EBITDA, asset and inventory turnover from [SA] (vendor ROA is EBIT-based). Interest coverage, DSO, DIO, DPO and CCC computed by analyst from [SA] year-end balances. FY2025 net debt/EBITDA and D/E are not meaningful (negative EBITDA and equity).
Trend commentary
Revenue. Nominal revenue grew strongly through FY2024 on inflation pass-through. It then fell 41% in FY2025, a period when Argentine inflation decelerated sharply, so the decline was severe in real terms. The company's own breakdown ([RAVA]): domestic sales (68.8% of total) fell 51.6% in pesos; exports fell only 5.1%. Biologicals fell 61.4%, pharmaceuticals 32.1%. Management attributed FY2025 to high costs and difficulty accessing credit for working capital, which prevented it from meeting sales plans. The collapse is therefore largely supply-side: an inability to finance production.
Gross margin. Margins swung between ~28% and ~46% during FY2021–FY2024. That volatility is typical of IAS 29 accounting, where the timing of inventory restatement against price increases distorts cost of sales. FY2025 turned negative (−4.5%) as cost of sales rose 19.8% (input-cost inflation per the company) while volumes collapsed. Fixed manufacturing overhead was then absorbed by far fewer units, a classic operating-deleverage pattern. Q1 2026 remained negative (gross loss ARS 263 M on ARS 1,504 M revenue), and the TTM to June 2026 shows only a marginal positive gross margin (2.7%).
Operating costs. SG&A was essentially flat in nominal pesos in FY2025 (ARS 2,449 M vs 2,428 M) while revenue fell, lifting SG&A/revenue from 22% to 38%. "Other operating expenses" jumped to ARS 634 M, likely provisions or impairments (detail not publicly disclosed).
Financial result. Results are dominated by below-the-line items. Interest expense doubled to ARS 1,651 M in FY2025. FX produced a ARS 3.5 bn loss in FY2024 and gains in FY2023 and FY2025. These swings imply significant USD-denominated liabilities, plausibly concursal debts and import payables, though the currency composition is not publicly disclosed. FY2023's profit relied on a ARS 687 M asset-sale gain and a ARS 1.7 bn FX gain; operating income was only ARS 34 M.
Balance sheet. Equity eroded from ARS 4.5 bn (FY2023) to negative by FY2025, and further to ARS −2.8 bn at Mar-2026 (company basis). Under Argentine company law (Ley General de Sociedades), loss of capital is a ground for dissolution unless remedied, which explains the urgency of the 2026 recapitalisation. Working capital turned negative (ARS −872 M). Accrued expenses more than doubled to ARS 3.85 bn, which likely includes tax and payroll arrears; the FY2025 cash flow shows a ARS 1.87 bn inflow from "change in income taxes", consistent with unpaid tax liabilities.
Cash flow. Operating cash flow stayed positive in every year, but it was largely produced by liquidating working capital (inventory release ARS 1.5 bn in FY2025, ARS 2.1 bn in FY2024) and accruing unpaid liabilities, not by earnings. Capex has been negligible since FY2024 (ARS 12–14 M per year against D&A of ARS 160–190 M), signalling underinvestment in the plant. Debt amortisation (ARS 839 M in FY2025) consumed all FCF, and cash fell 38%.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Contents | Representative products | Source |
|---|---|---|---|
Biological Products | Bacterial and viral vaccines for large and small animals | Reproductive-respiratory complex (IBR/BVD), brucellosis, carbunclo (anthrax), clostridial vaccines, equine vaccines, pneumonia and calf-diarrhoea vaccines, keratoconjunctivitis vaccine, canine and feline vaccines | [SA], [TV] |
Pharmaceutical Products | Chemical veterinary drugs | External and internal antiparasitics, endectocides, antimycotics/bacteriostatics, injectable antibiotics, antimastitics, other chemotherapeutics, vitamins and minerals | [SA], [TV] |
Others | Residual line, likely biolarvicides, diagnostics and miscellaneous items (composition not publicly disclosed) | Biolarvicides, diagnostic services, probiotics (analyst inference) | [TV], [BdC] |
Segment revenue (ARS Mn, derived)
| Segment revenue (ARS Mn, derived) | FY2024 | FY2025 |
|---|---|---|
Pharmaceutical Products | 5,272 | 3,580 |
Biological Products | 6,819 | 2,632 |
Others | 349 | 192 |
Total (derived) | 12,440 | 6,404 |
Segment share of revenue (%)
| Segment share of revenue (%) | FY2024 | FY2025 |
|---|---|---|
Pharmaceutical Products | 42.4 | 55.9 |
Biological Products | 54.8 | 41.1 |
Others | 2.8 | 3.0 |
Segment YoY growth, nominal ARS (%) | FY2025 | — |
Pharmaceutical Products | -32.1 | — |
Biological Products | -61.4 | — |
Others | -44.9 | — |
Income Statement
| Metric (ARS Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 1,523 | 4,276 | 9,860 | 10,886 | 6,404 |
Cost of revenue | 1,093 | 2,302 | 7,036 | 5,905 | 6,690 |
Gross profit | 429.2 | 1,974 | 2,825 | 4,980 | -286.03 |
SG&A | 397.23 | 1,054 | 2,517 | 2,428 | 2,449 |
Other operating expenses | -10.01 | 44.11 | 273.17 | 91.5 | 634.37 |
Operating income (EBIT) | 41.98 | 875.27 | 34.37 | 2,461 | -3,369 |
D&A | 45.1 | 85.72 | 106.89 | 160.55 | 192.08 |
EBITDA | 87.08 | 960.99 | 141.25 | 2,621 | -3,177 |
Interest expense | 67.42 | 524.56 | 1,058 | 822.99 | 1,651 |
FX gain (loss) | -114.02 | -318.06 | 1,709 | -3,504 | 556.45 |
Gain on sale of assets | 0 | 0 | 686.65 | 0 | 0 |
Pre-tax income | -38.11 | 32.65 | 1,371 | -1,866 | -4,463 |
Income tax expense | 8.43 | 74.9 | 134.85 | 245.29 | 50.87 |
Net income attributable | -38.12 | -25.22 | 1,226 | -1,864 | -4,598 |
Advertising expense | 4.34 | 9.55 | 21.43 | 16.7 | 10.51 |
Per share (ARS)
| Per share (ARS) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
EPS basic | -0.90 | -0.59 | 28.78 | -43.78 | -107.95 |
EPS diluted | -0.90 | -0.59 | 28.78 | -43.78 | -107.95 |
Dividends per share | 0 | 0 | 0 | 0 | 0 |
Book value per share | 8.10 | 26.53 | 97.89 | 87.80 | -18.79 |
Free cash flow per share | 1.27 | 1.66 | 5.07 | 16.59 | 9.34 |
Margin / growth (%)
| Margin / growth (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue growth (nominal) | 80.56 | 180.84 | 130.61 | 10.40 | -41.17 |
Gross margin | 28.19 | 46.16 | 28.65 | 45.75 | -4.47 |
Operating margin | 2.76 | 20.47 | 0.35 | 22.61 | -52.61 |
EBITDA margin | 5.72 | 22.48 | 1.43 | 24.08 | -49.61 |
Net margin | -2.50 | -0.59 | 12.43 | -17.13 | -71.80 |
SG&A / revenue | 26.08 | 24.65 | 25.53 | 22.30 | 38.24 |
Income Statement (Q1 2026 (3M to 31 Mar)–TTM to 30 Jun 2026)
| Metric (ARS Mn) | Q1 2026 (3M to 31 Mar) | TTM to 30 Jun 2026 |
|---|---|---|
Revenue | 1,504.2 | 6,813 |
Cost of sales | 1,767.4 | 6,632 |
Gross profit | -263.1 | 180.66 |
Operating income | — | -3,308 |
Net income | -466.3 | 183.57 |
FX gain | — | 1,588 |
Income tax (benefit) | — | -2,913 |
“—” = not publicly disclosed.
Balance Sheet
| Balance sheet (ARS Mn, year-end) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash & equivalents | 110.95 | 331.95 | 850.98 | 1,154 | 712.26 |
Receivables (total) | 386.07 | 1,035 | 2,969 | 2,426 | 1,927 |
Inventory | 580.1 | 1,639 | 4,762 | 4,127 | 2,608 |
Total current assets | 1,083 | 3,118 | 8,617 | 7,758 | 5,733 |
PP&E (net) | 361.4 | 1,023 | 2,318 | 2,143 | 1,992 |
Goodwill & intangibles | 0.09 | 10.12 | 29.35 | 0 | 0 |
Total assets | 1,456 | 4,198 | 10,981 | 9,921 | 7,745 |
Accounts payable | 171.68 | 432.2 | 1,797 | 648.73 | 761.78 |
Accrued expenses | 194.96 | 889.75 | 742.44 | 1,873 | 3,852 |
Total current liabilities | 542.21 | 1,700 | 4,109 | 4,329 | 6,605 |
Short-term debt (current portion) | 36.72 | 152.26 | 948.93 | 1,246 | 518.98 |
Long-term debt | 335.29 | 921.91 | 1,302 | 1,043 | 931.02 |
Total debt | 372.01 | 1,074 | 2,251 | 2,289 | 1,450 |
Net debt | 261.06 | 742.22 | 1,400 | 1,135 | 737.74 |
Total liabilities | 1,068 | 2,951 | 6,434 | 5,931 | 8,272 |
Common equity | 344.82 | 1,130 | 4,169 | 3,739 | -800.17 |
Minority interest | 43.18 | 117.44 | 378.59 | 250.87 | 273.98 |
Total equity | 388.01 | 1,247 | 4,548 | 3,990 | -526.19 |
Working capital | 541.06 | 1,418 | 4,509 | 3,429 | -872.37 |
Balance Sheet (31 Mar 2026–30 Jun 2026)
| Balance item (ARS Mn) | 31 Mar 2026 | 30 Jun 2026 | Pro-forma after Sep-2026 measures (on Mar-26 base) |
|---|---|---|---|
Total assets | 10,801.3 | 22,666 | — |
Total liabilities | 13,619.9 | 14,734 | — |
Total equity | -2,818.6 | 7,932 | 8,369 |
Current assets | 5,223.4 | 8,010 | — |
Current liabilities | 6,908.1 | 4,472 | — |
PP&E | 1,654 | 14,440 | — |
Accumulated deficit | -10,803.8 | 5,413 | — |
“—” = not publicly disclosed.
Cash flow (ARS Mn)
| Cash flow (ARS Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow | 58.37 | 153.37 | 331.37 | 720.31 | 409.89 |
Capital expenditure | 4.18 | 82.63 | 115.45 | 13.65 | 12.13 |
Free cash flow | 54.2 | 70.74 | 215.92 | 706.67 | 397.75 |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Net debt repaid | 84.1 | 84.29 | 87.8 | 672.28 | 839.33 |
Change in working capital (inflow) | 41.48 | -61.82 | -1,610 | 1,791 | 4,763 |
Net change in cash | -29.9 | -13.55 | 128.12 | 34.39 | -441.58 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | -15.24 | -5.17 | 42.68 | -49.47 | -260.63 |
ROA (%) | 2.12 | 19.35 | 0.28 | 14.71 | -23.84 |
ROIC (%) | 8.12 | -85.87 | 0.78 | 44.44 | -107.54 |
Current ratio (x) | 2.00 | 1.83 | 2.10 | 1.79 | 0.87 |
Quick ratio (x) | 0.92 | 0.80 | 0.93 | 0.83 | 0.40 |
Debt / equity (x) | 0.96 | 0.86 | 0.50 | 0.57 | -2.76 |
Net debt / EBITDA (x) | 3.00 | 0.77 | 9.91 | 0.43 | -0.23 |
Interest coverage EBIT/interest (x) | 0.62 | 1.67 | 0.03 | 2.99 | -2.04 |
Asset turnover (x) | 1.23 | 1.51 | 1.30 | 1.04 | 0.73 |
Inventory turnover (x) | 2.12 | 2.08 | 2.20 | 1.33 | 1.99 |
Days sales outstanding | 68 | 65 | 57 | 66 | 68 |
Days inventory outstanding | 172 | 175 | 166 | 274 | 183 |
Days payables outstanding | 57 | 69 | 93 | 40 | 42 |
Cash conversion cycle (days) | 183 | 172 | 130 | 300 | 210 |
Region revenue (ARS Mn, derived)
| Region revenue (ARS Mn, derived) | FY2024 | FY2025 |
|---|---|---|
Argentina (domestic) | 9,103 | 4,406 |
Exports (all markets) | 2,105 | 1,998 |
Region share (%)
| Region share (%) | FY2024 | FY2025 |
|---|---|---|
Argentina (domestic) | 81.2 | 68.8 |
Exports | 18.8 | 31.2 |
Region growth, nominal ARS (%) | FY2025 | — |
Argentina (domestic) | -51.6 | — |
Exports | -5.1 | — |
Valuation Snapshot
| Metric | Value | Period | Source |
|---|---|---|---|
Export sales | USD 1.3 M | 9M to Sep 2024 | [BdC] |
Export mix — biologicals | 65.96% | 9M 2024 | [BdC] |
Export mix — pharmaceuticals | 33.65% | 9M 2024 | [BdC] |
Number of export markets | More than 50 | Jan 2025 | [BdC] |
Recently opened markets | Libya, Oman, Dubai (UAE), to be consolidated via local distributors | Jan 2025 | [BdC] |
Subsidiaries abroad | Paraguay (confirmed 2025); Brazil and Uruguay per aggregator | 2011–2025 | [BdC], [INV], [BW] |
Valuation Snapshot — Last close
| Metric | Value | Source |
|---|---|---|
Last close | ARS 143.50 (6 Oct 2026) | [RAVA] |
52-week range | ARS 116.00 – 357.00 | [SA] |
YTD 2026 | −40.33% | [RAVA] |
1-year (6 Oct 2025 close ARS 129.00) | +11.2% nominal ARS | [RAVA], analyst computation |
3-year (FY2023 close ARS 64.00, approx.) | +124% nominal ARS | [SA], analyst computation |
~5-year (FY2021 close ARS 11.00, approx.) | +1,205% nominal ARS (negative or modest in real/USD terms given cumulative inflation and devaluation) | [SA], analyst computation |
Beta | 0.03 [SA] / 0.41 [RAVA] (illiquid; not meaningful) | [SA], [RAVA] |
Average daily volume | ≈ 17,000 shares (≈ ARS 2.4 M) | [RAVA] |
Year-end price (ARS) | FY2021 | FY2022 |
Closing price | 11.00 | 12.90 |
Market capitalisation (ARS Mn) | 468 | 549 |
Enterprise value (ARS Mn) | 615 | 772 |
Valuation Multiples
| Multiple (x) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
P/E | 0 | 0 | 2.22 | 0 | 0 |
P/S | 0.31 | 0.13 | 0.28 | 0.48 | 1.60 |
P/B | 1.21 | 0.44 | 0.60 | 1.30 | -19.47 |
EV/Sales | 0.40 | 0.18 | 0.33 | 0.56 | 1.84 |
EV/EBITDA | 7.06 | 0.80 | 22.77 | 2.32 | 0 |
P/FCF | 8.64 | 7.77 | 12.62 | 7.35 | 25.75 |
Capital Markets
| Item | Status | Source |
|---|---|---|
Dividend history | Never paid | [TV] |
Dividend policy | None disclosed; legally constrained by accumulated losses | Analyst |
Credit ratings (Moody's / S&P / Fitch / local) | None identified | — |
Debt maturity profile | FY2025: current ARS 519 M, non-current ARS 931 M. Jun-2026: current ARS 414 M, non-current ARS 2,654 M (non-current rose, possibly from rescheduling or new controller funding). Detailed schedule not disclosed. | [SA] |
Pending dilution | Capitalisation of controller and trust credits (assembly agenda); size not disclosed | [RAVA] |
Analyst Conclusions
Guidance and consensus
No management guidance and no sell-side consensus exist. The only forward indicators are (a) the controller's stated intention to execute an investment plan to restore financial health and (b) the balance-sheet measures approved in September 2026. TTM revenue to June 2026 (ARS 6.8 bn) is slightly above FY2025 (ARS 6.4 bn), suggesting stabilisation of the top line but not yet a recovery in real terms. Q1 2026 still showed a gross loss.
Bull case
-
Balance-sheet reset unlocks working capital. With equity restored (≈ ARS 8 bn) and ARS 1.94 bn of controller debt forgiven, the company can again access trade credit and bank lines. Biologicals revenue, down 61% in FY2025, could recover toward FY2024 levels and restore gross margins of 40%+ seen in FY2022 and FY2024.
-
Strategic owner with a distribution network. Agro 2000's farm-input reach can push Rosenbusch products through an existing channel at low incremental SG&A. Operating leverage on a fixed SG&A base (≈ ARS 2.4 bn) is substantial.
-
Deep asset backing. At ARS 6.1 bn market cap against ≈ ARS 14.4 bn of revalued PP&E and positive Jun-2026 equity of ARS 7.9 bn, the stock trades below book (P/B 0.77x). The OPA's financed "fair price" of USD 0.1785 implies roughly 85% upside to the ~USD 0.096 market-implied price.
Bear case
-
Revaluation is not cash. About ARS 9.2 bn of the ≈ ARS 11.2 bn equity improvement is a non-cash accounting remeasurement. The operating business lost ARS 3.3 bn at EBIT level in the TTM to June 2026, and the Q1 2026 gross margin was negative.
-
Minority value leakage. The OPA offered either 17-year deferred payment or a cash price (~USD 0.08) below market. Capitalisation of controller credits could dilute minorities. A future delisting could strand the 19.84% float.
-
Structural competitive disadvantage. Years of near-zero capex, no disclosed R&D, and FMD-deregulation-driven price competition led by a national champion (Biogénesis Bagó) heading toward USD 300 M of revenue leave Rosenbusch exposed in its core biologicals franchise.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| Shareholders' assembly approving debt forgiveness and credit capitalisation | Q4 2026 | Determines final equity and minority dilution |
| Q3 2026 results | Vendor estimate 17 Dec 2026 | First full quarter under the new balance sheet; watch gross margin |
| FY2026 annual report | ~Apr 2027 | Full-year turnaround evidence; auditor opinion on going concern |
| BYMA trading regime | Ongoing | Removal of "special warnings" status would signal normalised disclosure |
| Capital increase or rights offering | Undetermined | Fresh cash versus non-cash restructuring |
| Delisting decision | Undetermined | Minority liquidity risk |
| Biologicals production restart (volumes, export orders) | 2026–27 | Core franchise recovery |
| Management appointments and strategy disclosure from Agro 2000 | 2026–27 | Visibility on plan, capex and targets |
Analyst verdict
Instituto Rosenbusch is a heritage Argentine animal-health brand emerging from an operational and financial collapse under new ownership. The FY2025 numbers are as bad as industrial accounts get: revenue down 41%, a negative gross margin, a net loss larger than 70% of sales, and negative equity. Q1 2026 confirmed that losses had not stopped at the time of the takeover. Positive operating cash flow over the past five years was largely a liquidation of inventory and an accumulation of unpaid liabilities, not proof of earnings power.
The September 2026 measures change the legal and accounting picture more than the economic one. Forgiving ARS 1.94 bn of intercompany debt is a real transfer from the controller. The ARS 12.3 bn revaluation, by contrast, simply recognises that an owned urban plant and its equipment were carried far below replacement value. Together they remove the immediate capital-loss threat and make the company financeable. Neither puts cash into production of vaccines or antiparasitics. The turnaround thesis therefore rests on three unproven premises: that Agro 2000 will inject working capital (directly or through credit lines enabled by the new balance sheet); that biologicals production can be restored at competitive cost in an increasingly open market; and that the controller's distribution footprint can rebuild domestic share.
For minority investors, the governance record since February is a material negative. The OPA offered a 17-year instalment plan or a cash price below the market, and no holder accepted. Further dilution through credit capitalisation remains possible. The stock trades below revalued book, which is defensible given the uncertainty.
Verdict: Speculative turnaround. Upgrading this view would require two consecutive quarters of positive gross margin, disclosure of a funded capex and working-capital plan, and clarity on credit-capitalisation terms. Absent these, the market-implied ~USD 4 M equity value appears a fair reflection of a distressed option on a brand and a building.
*End of dossier. All figures in ARS unless stated; USD conversions are approximate.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure / context | Source |
|---|---|---|---|
Félix Agustín Gaibisso | President of the Board | In office by Sep 2026 (signed Hecho Relevante of 11 Sep 2026); presumed appointed after the Feb 2026 change of control | [RAVA] |
Dr. Rodolfo Martín Balestrini | Former Chairman of the Board and President (still listed by data vendors) | Pre-2026 family leadership; status after the sale not publicly disclosed | [SA], [INV] |
Oscar Echeverria | Financial Manager (per data vendor) | — | [SA] |
Andrés Balestrini | Director (historical) | Since 2006 | [INV] |
Mónica Eva Lukesch | Director (historical) | — | [INV] |
Ramón Antonio Maynard | Member, Supervisory Committee (Comisión Fiscalizadora) (historical) | — | [INV] |
Armando Manuel Silvariño | Member, Supervisory Committee (historical) | — | [INV] |
José Carlos Rognoni | Member, Supervisory Committee (historical) | — | [INV] |
“—” = not publicly disclosed.
Governance Overview
| Item | Status | Source |
|---|---|---|
Audit Committee | Exists; issued a favourable prior opinion on the Agro 2000 debt-forgiveness proposal (Sep 2026) | [IP], [RAVA] |
Supervisory Committee (Comisión Fiscalizadora) | Exists (historically three members) | [INV] |
Board meeting minute numbering | Minute No. 1401 (11 Sep 2026) | [RAVA] |
Independence ratio | Not publicly disclosed (CNV rules require independent members on the Audit Committee) | — |
Chair/CEO separation | Historically combined (the Chairman was also President, the executive role in Argentine S.A.s); post-2026 not disclosed | [SA] |
Dual-class structure | Class A shares (5 votes) and Class B (1 vote). Only 192 Class A shares are in the free float; Class A held by the controller is not disclosed. | [RAVA] |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
10 Feb 2026 | Control passes from Rinder, San Teobaldo and Balestrini family members to Agro 2000 S.A. (80.16%) | Ends roughly a century of founding-family control. The sale included all credits the former shareholders held against the company. The new shareholders committed to converting these into irrevocable contributions toward future capital increases. [IP], [RAVA] |
2026 (date not disclosed) | Félix Agustín Gaibisso becomes President | New controller's nominee (analyst inference) |
Major Shareholders
| Holder | Shares (approx.) | Stake | Source |
|---|---|---|---|
Agro 2000 S.A. (Córdoba-origin agribusiness inputs and services company) | 34.14 M | 80.16% | [IP], [RAVA] |
Free float (public; individual holders not disclosed) | 8.45 M | 19.84% | [RAVA] |
Competitive Landscape
Key Competitors
| Competitor | Ownership / type | Overlapping segments | Scale and positioning | Source |
|---|---|---|---|---|
Biogénesis Bagó | Argentine private (Bagó group / Insud) | Biologicals (FMD, rabies, clostridial, reproductive), pharmaceuticals, companion animals | Dominant national biologicals player: decades as main FMD vaccine supplier (~100 M doses/yr in Argentina), antigen-bank supplier to Argentina, US, Canada, Korea, Taiwan, and Brazil (Dec 2025). CEO targets USD 300 M revenue by 2027. | bichosdecampo.com; mercado.com.ar |
Centro de Diagnóstico Veterinario (CDV) | Argentine private | Biologicals (FMD and others), diagnostics | More than 60 products exported to 30 markets; minority FMD share | bichosdecampo.com |
Tecnovax | Argentine private | Biologicals (FMD entrant via Brazilian supply, cattle vaccines) | Challenger in the deregulated FMD market | bichosdecampo.com |
Over (Laboratorios Over) | Argentine private | Pharmaceuticals (antiparasitics, antibiotics), exports | Strong national exporter | [BdC] related coverage |
Laboratorios König | Argentine private | Pharmaceuticals, companion animals | National mid-size player (financials not publicly disclosed) | Analyst knowledge |
Holliday-Scott | Argentine private | Pharmaceuticals (antiparasitics, endectocides) | National mid-size player (financials not publicly disclosed) | Analyst knowledge |
Zoetis | US-listed multinational | Livestock and companion-animal biologicals and pharmaceuticals | — | Analyst knowledge |
MSD Animal Health (Merck & Co.) | Multinational | Biologicals, antiparasitics | Global top-3 | Analyst knowledge |
Boehringer Ingelheim Animal Health | Multinational (private parent) | Biologicals, endectocides | Global top-3 | Analyst knowledge |
Elanco | US-listed multinational | Pharmaceuticals, parasiticides | — | Analyst knowledge |
Ceva Santé Animale | French private | Biologicals, reproduction | Strong in ruminant reproduction and LatAm vaccines | Analyst knowledge |
Valent BioSciences / other Bti larvicide suppliers | Multinational | Biolarvicides (vector control) | Global leaders in biological mosquito control | Analyst knowledge |
Peer Comparison FY2025
| Metric | Rosenbusch FY2024 | Rosenbusch FY2025 | Zoetis FY2024 | Elanco FY2024 | Biogénesis Bagó |
|---|---|---|---|---|---|
Revenue | ≈ USD 11 M (ARS 10,886 M) | ≈ USD 5 M (ARS 6,404 M) | ≈ USD 9,300 M | ≈ USD 4,400 M | Not disclosed (target USD 300 M by 2027) |
Revenue growth (local currency) | +10.4% nominal ARS (negative real) | −41.2% nominal ARS | ≈ +8% | ≈ +1% | ~14%/yr in FMD and rabies over the prior three years (per CEO) |
Gross margin | 45.8% | −4.5% | ≈ 70% | ≈ 55% | — |
Operating (EBIT) margin | 22.6% | −52.6% | ≈ 36% | Low single digit (GAAP) | — |
R&D intensity | — | — | ≈ 7% of revenue | ≈ 8% of revenue | — |
“—” = not publicly disclosed.
Recent Developments
Every identifiable material item is listed (fewer than the 25 requested; no further items were found).



